RightFit
RecruitingPhase not listed

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

Pathophysiologic Mechanisms Leading to Intrahepatic Fat Accumulation in Obese Youth

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
12 Years to 18 Years
Sex
All sexes
Healthy volunteers
Not stated
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The main aim of the study is to discover the mechanisms underlying the pathophysiology of NAFLD in obese youth.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria: * Good general health, taking no medication on a chronic basis; * age 12 to 18 years, in puberty (girls and boys: Tanner stage II-V); * BMI \>85th for obese cohort; Exclusion Criteria: * Baseline creatinine \>1.0 mg; pregnancy; * the presence of endocrinopathies (e.g. Cushing syndrome); * cardiac or pulmonary or other significant chronic illness; * adolescents with a psychiatric disorder or with substance abuse; * monogenic obesity syndromes; * use of drugs affecting intrahepatic fat content (e.g.; liraglutide, fish oil, etc.).

Study sites (1)

CT